Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2021 | Analysis of the EORTC/FIL/LYSA H10 and RAPID trials

Igor Aurer • 7 Jun 2021
ICML 2021
Hodgkin Lymphoma Lymphoma Bleomycin Dacarbazine Doxorubicin Vinblastine
H10 RAPID

Igor Aurer, MD, PhD, University of Zagreb, Zagreb, Croatia, discusses recent analysis of the Phase III EORTC/FIL/LYSA H10 (NCT00433433) and UK NCRI RAPID trials (NCT00943423). Both studies concluded that patients with Hodgkin lymphoma (HL) receiving ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) but no radiotherapy had an increased risk of relapse but an unaffected overall survival (OS). The H10 trial additionally concluded that sex and stage of the disease affected prognosis, but this was not reproducible with data from the RAPID trial. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).

More from Igor Aurer

2:07
Treating relapse in HL
Igor Aurer • 7 Jun 2021
2:13
Risk stratification and personalized treatment in HL
Igor Aurer • 7 Jun 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals